Exploring heterogeneity in treatment effects: The impact and interaction of asset-based wealth and mass azithromycin distribution on child mortality
PLOS One · 2026
DOI: 10.1371/journal.pone.0341665 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift PLOS One, 2026. Verfasst von Elisabeth A Gebreegziabher und 16 weiteren Autor:innen. Beteiligte Einrichtung: Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States of America. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azithromycin, Child Mortality. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, Bill and Melinda Gates Foundation, National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Objective
To examine how child mortality among children aged 1–59 months varies by asset-based wealth status in rural Burkina Faso, and to assess the interaction between mass azithromycin (AZ) distribution and wealth status on child mortality at both the household and community levels.
Methods
We used data from a cluster-randomized trial and population census data on household characteristics and assets. A wealth index score for each household, used to classify the population by wealth, was generated using principal component analysis. We used the Relative Index of Inequality (RII), the Slope Index of Inequality (SII), and the concentration index to assess wealth-related inequalities in mortality, and the Gini Index to assess variability in child mortality across households and communities. Poisson regression models were used, with person-time at risk included as an offset, and robust standard error to estimate changes in mortality rates by wealth and treatment arm. Interaction was assessed on both the multiplicative and additive scales.
Results
Mortality declined with increasing wealth at both the household and community levels, with a significant gradient at the community level (RII = 1.17, 95% CI: 1.05–1.29; SII = 2.3 per 1,000 person-years, 95% CI: 0.2–4.4), reflecting higher mortality among the poorest. The effect of AZ did not vary significantly by wealth index, and changes in mortality rates across wealth levels were similar between the two treatment arms. There was no evidence of a statistically significant interaction between AZ and asset-based wealth on either the multiplicative or additive scale at the household or cluster level.
Conclusion
Our findings demonstrate a wealth gradient in child mortality, with the highest mortality rates observed among households and communities in the lowest wealth quintiles. These disparities were consistent across both AZ-treated and placebo groups, suggesting that the role of AZ in health disparities may be limited to addressing gaps in treatment access rather than broader wealth-related disparities. While the study may have been underpowered to detect modest interaction effects, AZ appeared to offer similar benefits across economically diverse communities, with no evidence suggesting enhanced benefits for disadvantaged communities or for prioritizing treatment based on wealth status. Further work is needed to address the wealth-related disparities in child mortality in these communities.
Trial registration
ClinicalTrials.gov NCT03676764
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States of America.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, United States of America.
- Centre de Recherche en Sante de Nouna, Nouna, Burkina Faso.
- Department of Medicine, University of California, San Francisco, California, United States of America.
- Department of Ophthalmology, University of California, San Francisco, California, United States of America.
- Institute for Global Health Sciences, University of California, San Francisco, United States of America.
ORCID-Profile: Elisabeth A Gebreegziabher, Pearl Anne Ante-Testard, Kieran S O'Brien
Förderung
- NICHD NIH HHS
- Bill and Melinda Gates Foundation
- National Institute of Child Health and Human Development
Zitieren
APA
Gebreegziabher, E. A., Sié, A., Ouattara, M., Bountogo, M., Coulibaly, B., Boudo, V., Ouedraogo, T., Lebas, E., Hu, H., Ante-Testard, P. A., Gregorich, S. E., O'Brien, K. S., Hsiang, M. S., Glidden, D. V., Arnold, B. F., Lietman, T. M., & Oldenburg, C. E. (2026). Exploring heterogeneity in treatment effects: The impact and interaction of asset-based wealth and mass azithromycin distribution on child mortality. PLOS One. https://doi.org/10.1371/journal.pone.0341665
Vancouver
Gebreegziabher EA, Sié A, Ouattara M, Bountogo M, Coulibaly B, Boudo V, et al. Exploring heterogeneity in treatment effects: The impact and interaction of asset-based wealth and mass azithromycin distribution on child mortality. PLOS One. 2026. doi:10.1371/journal.pone.0341665
BibTeX
@article{Gebreegziabher2026,
author = {Gebreegziabher, Elisabeth A and Sié, Ali and Ouattara, Mamadou and Bountogo, Mamadou and Coulibaly, Boubacar and Boudo, Valentin and Ouedraogo, Thierry and Lebas, Elodie and Hu, Huiyu and Ante-Testard, Pearl Anne and Gregorich, Steven E and O'Brien, Kieran S and Hsiang, Michelle S and Glidden, David V and Arnold, Benjamin F and Lietman, Thomas M and Oldenburg, Catherine E},
title = {Exploring heterogeneity in treatment effects: The impact and interaction of asset-based wealth and mass azithromycin distribution on child mortality},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0341665}
}
EUVIMED